Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence
Andreas Wollenberg(University Hospital Augsburg), Slawomir Lazarewicz(Novartis (Switzerland)), Simon Francis Thomsen(University of Copenhagen), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), Xavier Jaumont(Novartis (Switzerland))
Cited by 139
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Thin Stage I Primary Cutaneous Malignant Melanoma
|New England Journal of Medicine|1988|564